|
March 4, 2003, Mountain View and Brisbane, California - SurroMed, Inc.
and InterMune, Inc. announced today that they have entered into an
agreement for the discovery of biomarkers for use in InterMune's applied
research efforts. Under the terms of the agreement, InterMune will
supply clinical samples for analysis in SurroMed's Biomarker Discovery
Laboratory. SurroMed will analyze the samples using its integrated
suite of mass spectrometry based technologies. Financial terms of
the agreement were not disclosed.
"We are delighted to have the opportunity to work with InterMune to
advance its applied research efforts," said Nancy Grove, MD,
Vice President of Biomarker Discovery Services of SurroMed.
"Our quantitative differential protein and small organic molecule
profiling capabilities provide a unique combination of sensitivity,
throughput and reproducibility that enable rapid and effective
biomarker identification."
SurroMed's integrated biomarker discovery program combines proprietary
sample preparation techniques with advanced high-resolution mass
spectrometric methods for the differential analysis of biological
samples. Subsequently, detailed bioanalytical data is analyzed and
mined using SurroMed's suite of informatics tools. Biomarker analysis
and profiling has multiple applications across all stages of the drug
discovery and development continuum from preclinical analysis of animal
samples to follow-up evaluation of patients already receiving marketed
products.
"We are pleased to initiate work with SurroMed's proteomic technology
to accelerate discovery of key biomarkers for our research programs,"
said Lawrence M. Blatt, Ph.D., Vice President of Biopharmacology at
InterMune. "This effort will help us better understand drug response
in some of our ongoing clinical trials as well as assist our discovery
efforts in identifying new drug therapies for pulmonary and hepatic
disease."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed is pioneering
biomarker enabled drug discovery and development. The company focuses
on discovering and applying biomarkers to improve the drug discovery
and development process and enable the precise diagnosis and personalized
treatment of disease. SurroMed's research process yields biological
markers and information that enable accelerated, cost-efficient discovery
and development of new therapeutic products, as well as development of
diagnostic tests for early disease detection, disease staging, patient
stratification, and guiding and monitoring therapy.
About InterMune
InterMune is a commercially driven biopharmaceutical company focused
on the marketing, development and applied research of life-saving
therapies for pulmonary disease, infectious disease and hepatology.
For additional information about InterMune, please visit www.intermune.com.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Ian McConnell, Ph.D
Senior Account Executive
(415) 677-4455 ext. 233
email: [email protected]
|
